Together, these analyses show that REST targets are largely distinct from ASCL1 targets and support a model in which both inhibition of the pro-NE transcription factor ASCL1 and activation of the REST repressor contribute to the NE to non-NE cell fate change observed in SCLC downstream of Notch signaling activation. The gene discussed is ASCL1; the disease is small cell lung carcinoma.